{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Allakos Inc."},"Symbol":{"label":"Symbol","value":"ALLK"},"Address":{"label":"Address","value":"975 ISLAND DRIVE SUITE 201, REDWOOD CITY, California, 94065, United States"},"Phone":{"label":"Phone","value":"+1 650 597-5002"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells."},"CompanyUrl":{"label":"Company Url","value":"https://www.allakos.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Adam L. Tomasi","title":"President &amp; Chief Operating Officer"},{"name":"Robert Alexander","title":"Chief Executive Officer &amp; Director"},{"name":"Ruby Casareno","title":"Vice President-Technical Operations"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}